Browse the evidence

Both GLP-1RAs and combination therapy resulted in significant weight loss, with GLP-1RAs showing a mean weight loss of −5.2 kg at 12 months.

Practitioners can expect GLP-1RAs to aid in weight management for liver transplant recipients with diabetes.

The automated, online, behavioral obesity treatment program (Rx Weight Loss) produced a mean estimated weight loss of 3.60 kg at 3 months.

Practitioners can consider automated online programs as effective for initial weight loss.

At 12 months, weight regain was significantly less in the monthly and refresher maintenance groups compared to the newsletter control group.

Ongoing maintenance interventions are essential to prevent weight regain after initial weight loss.

The pragmatic implementation of the Rx Weight Loss program resulted in clinically significant weight loss over 2 years.

Clinicians can implement automated online obesity treatments for sustained weight management.

GLP-1s reduce body weight by 5% to 18% in trials.

Clinicians can expect significant weight loss in patients using GLP-1s.

Evidence-based nutritional and lifestyle strategies are crucial for effective GLP-1 treatment.

Clinicians should integrate nutritional and lifestyle interventions to enhance GLP-1 treatment outcomes.

Tirzepatide resulted in greater hemoglobin A1c reduction from baseline compared to placebo and active comparators, with absolute reductions up to 3.02%.

Tirzepatide may be a more effective option for lowering blood sugar in patients with type 2 diabetes.

Tirzepatide was associated with significant weight loss.

Tirzepatide may aid in weight management for patients with type 2 diabetes.

Ten days of low energy availability (LEA) resulted in impaired performance in trained females, with reductions in muscle glycogen content and physical performance parameters.

Athletes should be cautious about using low energy availability strategies as they may impair performance.

GLP-1 receptor agonists are effective agents for weight loss.

Practitioners can consider GLP-1 receptor agonists as a viable option for weight loss in patients.

Tirzepatide shows great efficacy in glycosylated hemoglobin and weight reduction.

Tirzepatide may be effective for improving glycemic control and promoting weight loss in diverse patient groups.

GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.

GLP-1 RAs may be considered as a pharmacologic option for obesity treatment.

Semaglutide and liraglutide have been approved as weight loss medications due to their effectiveness in promoting significant and sustained weight loss.

Clinicians can prescribe semaglutide and liraglutide for weight management in eligible patients.

Weight loss can improve obesity-related comorbidities such as metabolic syndrome, diabetes, cardiovascular disease, and obstructive sleep apnea.

Weight loss should be emphasized in preoperative counseling for patients with obesity.

GLP-1 agonists resulted in a percentage of change in body weight of -6.2% at six months.

GLP-1 agonists may be an effective option for weight loss in obese IBD patients.

58.3% of patients achieved a weight reduction of 5% or more at six months.

A significant portion of obese IBD patients may benefit from GLP-1 agonist therapy for weight loss.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.

Tirzepatide may be beneficial for weight management in patients with obesity.

HU6 treatment for 19 weeks significantly decreased body weight by -2.86 kg compared to placebo (P = .003).

HU6 may be an effective treatment option for weight loss in patients with obesity-related HFpEF.

HU6 treatment significantly decreased total fat mass by -2.96 kg compared to placebo (P < .001).

HU6 may help reduce fat mass in patients with obesity-related HFpEF.

Gastric band (GB) surgery achieved a median weight loss of 9.8% at 10 years compared to 5.6% in the medical group (median difference 4.2%; p = .008).

GB surgery may be a more effective option for weight loss in overweight individuals with type 2 diabetes compared to medical care.

Diabetes remission occurred in five GB participants and no medical participants (relative risk 0.76, 95% CI: 0.55-0.93, p = .048).

GB surgery may increase the likelihood of diabetes remission in overweight individuals with type 2 diabetes.

Semaglutide is safe and effective for weight loss in obese, non-diabetic patients with end-stage kidney disease on haemodialysis.

Practitioners may consider semaglutide as a treatment option for weight loss in similar patient populations.

Weight-lowering approaches such as bariatric surgery and treatment with semaglutide and tirzepatide can alleviate both cardiovascular diseases (CVD) and nonalcoholic fatty liver disease (NAFLD).

Practitioners should consider weight loss interventions as effective strategies for managing NAFLD and CVD.